AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01064375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derma Vax (electroporation device)
Description: Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration
Study NCT01064375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF will be given for 4 consecutive days starting the day before the vaccination as an intradermal/subcutaneous administration of 150 ug of GM-CSF
Study NCT01064375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
Study NCT03476005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: proficiency based progression training
Description: proficiency based progression training supported by technology enhanced learning
Study NCT03869463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: Participants will complete 8 weeks of computerized cognitive training through the Peak platform on mobile devices.
Study NCT03869463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training
Description: Participants will complete 8 weeks of computerized cognitive training through the Peak platform on mobile devices.
Study NCT03869463 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This group will not receive computerized cognitive training.
Study NCT01232036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage 500mg
Description: Single Oral Dose of
Study NCT01232036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-018 500mg
Description: Single Oral Dose of
Study NCT01232036 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No administration of Drug
Study NCT02644616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolvaptan+torasemide
Description: tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv
Study NCT02644616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo+torasemide
Description: placebo 15mg/d po(10 days) +torasemide 20mg/d iv
Study NCT01755026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin
Description: 2 gram dose for pre-operative prophylaxis
Study NCT01755026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefazolin
Description: 4 gram dose for pre-operative prophylaxis
Study NCT02238184 — intervention group
Intervention type: DRUG
Intervention: Atrovent®
Study NCT02238184 — intervention group
Intervention type: DRUG
Intervention: Ventilat®
Study NCT00973011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCFD4514S
Description: Intravitreal escalating dose
Study NCT02971033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg ezetimibe
Description: Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.
Study NCT02971033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants assigned to this intervention will receive placebo every day for 12 weeks
Study NCT02971033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg ezetimibe
Description: Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.
Study NCT04155242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytosponge test
Description: The Cytosponge will be administered by the study nurse prior to the participant having the endoscopy, usually as part of the same visit to hospital. The capsule along with the string is swallowed by drinking a small glass of water. The participant is asked to hold the Cytosponge in situ for 5 minutes. The sponge contained within expands and is then drawn back by the research nurse up the oesophagus by the attached string, collecting cells as it moves upwards. This device received a letter of no objection by the MHRA for use in the BEST pilot trial (LRQ 0939857) but it is not CE marked. Cytosponge and research endoscopic biopsies will be couriered to the Fitzgerald laboratory, at the MRC Cancer Cell Unit on a regular basis. The specimens will be processed in conjunction with the Cambridge University Hospitals' NHS Foundation Trust tissue bank which is accredited to GLP standards.
Study NCT04155242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of the panel of molecular biomarkers: IM-SCORE, TFF3 protein expression, methylation panel, p53 mutation
Description: Molecular analysis of the specimen obtained by Cytosponge or endoscopic biopsies - TFF3 protein expression, methylation panel, p53 mutation. Endoscopic biopsies will be assessed for the presence of IM (according to the IM-score).
Study NCT04155242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oesophagogastroduodenoscopy
Description: * Endoscopy will be carried out with white light and NBI with optical magnification or near focus to inspect oesophagus and GOJ.~* NBI magnification will be used to assess systematically the mucosal pit pattern at the GOJ and to look for light blue crest (LBC) sign.~* Targeted biopsies will be taken from either areas with LBC or irregular pit pattern on NBI, followed by random biopsies as per clinical standard. A maximum of 6 biopsies will be taken at the GOJ (maximum 4 targeted and 4 random.. During the first 2 post RFA follow up, at discretion of the endoscopists, neo-suqamous biopsies can be taken in line with local policies.~* Argon plasma coagulation ablation is allowed in a single island up to 5mm or up to 3 islands \<3mm within the study endoscopy as long as this does not represent an obstacle to GOJ biopsies.
Study NCT03697889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (test product)
Description: Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.
Study NCT03697889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (reference product)
Description: Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.
Study NCT04363788 — intervention group
Intervention type: PROCEDURE
Intervention: double gloves
Description: The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
Study NCT02935283 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: MRI, fMRI, 1H MRS, DTI
Study NCT01828931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: A lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity
Study NCT01828931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Care as usual
Study NCT01819779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exforge tab. 10/160mg
Study NCT01819779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodivixx tab. 5/160mg
Study NCT02836015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Medical Visit
Description: The Shared Medical Visits are a replacement for standard diabetic visits with PCP, and will occur completely in Spanish, the patients' preferred primary language. An interdisciplinary group including behavioral health, social work, pharmacy, MD, and diabetic educator will be involved in the visit. The focal point of the meeting is a 30 minute session in which all members are seated around a large table in the Midtown SMV area and each patient's blood sugars, labs, and medications are discussed in front of the entire group. Pertinent labs and vaccines are drawn/administered.
Study NCT03442673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Stimulation with vinorelbine together with G-CSF for mobilization of autologous stem cells
Study NCT03442673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Stimulation with gemcitabine together with G-CSF for mobilization of autologous stem cells
Study NCT03442673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Cytokine stimulation with G-CSF for mobilization of autologous stem cells
Study NCT03442673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Cytokine stimulation with G-CSF for mobilization of autologous stem cells
Study NCT02935283 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral
Description: Battery of executive function tasks
Study NCT02802917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y49 091 (BAY 987516)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Study NCT02802917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 X15 158 (BAY 987516)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Study NCT02802917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 X15 160 (BAY 987516)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Study NCT02802917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 X57 162 (BAY 987516)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Study NCT02802917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: J & J baby shampoo, X46 046 (control)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Study NCT02365233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP4 inhibitor
Description: Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Study NCT02365233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Study NCT02365233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus insulin
Description: Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Study NCT04934917 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging. Pain testing: Temporal summation, Pain thresholds. Assessment of symptoms: Questionnaires. All interventions are made at baseline only (1 time/subject).
Study NCT00986297 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: hypofractionated radiation therapy
Description: hypofractionated radiation therapy
Study NCT03277235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience model-based total care plan
Description: 12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
Study NCT02459288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel first
Description: After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
Study NCT02459288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor first
Description: After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
Study NCT03618290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analyze plasma free fatty acid in blood
Description: This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression.
Study NCT02081885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricalcium Phosphate / Chitosan
Study NCT02081885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Graft
Study NCT00529607 — intervention group
Intervention type: DRUG
Intervention: contrast echocardiography
Description: directly after PCI, at 24 h after PCI, before discharge and at 6 months
Study NCT00529607 — intervention group
Intervention type: PROCEDURE
Intervention: 2D and 3D echocardiography
Description: directly after PCI, at 24 h after PCI, before discharge and at 6 months
Study NCT00529607 — intervention group
Intervention type: PROCEDURE
Intervention: cardiac MRI
Description: before discharge and after 6 months
Study NCT00529607 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling
Description: routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3
Study NCT00225264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
Study NCT00225264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
Study NCT01087788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Description: 200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
Study NCT01087788 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 200 mg Q2W
Description: 200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
Study NCT01087788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q4W
Description: 400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
Study NCT01087788 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 400 mg Q4W
Description: 400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
Study NCT01087788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo to CZP injection.
Study NCT01087788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to CZP injection.
Study NCT01087788 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo to CZP injection.
Study NCT03159962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bonded RME (Rapid Maxillary Expander) appliance
Description: The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months.
Study NCT03159962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Banded RME (Rapid Maxillary Expander) appliance
Description: The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months.
Study NCT02335814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX925
Study NCT01831583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of PPG waveforms
Description: The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.
Study NCT01831583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of Pulse Arrival Time (PAT)
Description: The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
Study NCT03225040 — intervention group
Intervention type: DRUG
Intervention: Pegvisomant
Description: Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
Study NCT01348477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elliptical domed mesh technique
Description: A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
Study NCT01348477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elliptical domed mesh technique
Description: A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
Study NCT02277561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion tensor imaging
Description: Undergo VB-DTI
Study NCT02277561 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole-brain radiation therapy
Description: Undergo WBRT
Study NCT02277561 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo SRS
Study NCT02277561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contrast-enhanced magnetic resonance imaging
Description: Undergo contrast-enhanced MRI
Study NCT02277561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo DW MRI
Study NCT02158429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 dimensional vs. 3 dimensional ultrasound
Description: At the end of a regularly scheduled ultrasound measuring fetal growth an additional 5-10 minute ultrasound will be performed, either in 2-dimensional or 3-dimensional mode
Study NCT02878161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate(necessary)
Description: Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.
Study NCT02878161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infliximab :intravenous injection 200mg,every times,0,2,6,14week ,4 times)
Study NCT02878161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Etanercept :hypodermic injection,25mg/twice a week
Study NCT02878161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab:hypodermic injection,40mg/twice a week
Study NCT02878161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide (permitted, not necessary)
Description: LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
Study NCT02878161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs (permitted,not necessary)
Description: NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
Study NCT02878161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (permitted,not necessary)
Description: Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.
Study NCT02796417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REHACOP
Description: REHACOP group consists of 90-minute-long sessions 3 days per week. Specifically, REHACOP group remediation consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas
Study NCT02796417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational activities
Description: Occupational group activities conducted included drawing, gardening, reading the daily news and constructing using different materials (such as paper or wood).
Study NCT03810872 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib
Description: Open label
Study NCT03810872 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel
Study NCT01947855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching Empagliflozin low dose
Study NCT01947855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin low dose
Study NCT01947855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching Empagliflozin high dose
Study NCT01947855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching Empagliflozin low dose